Biocomposites, an international medical devices company, completed the investment in Renovos Biologics, an innovative biologics company. Financial terms were not disclosed. "The potential for RENOVITE® as a next generation drug carrier that can enhance the activity of therapeutic drugs at lower doses, whilst giving the surgeon much greater freedom to use in minimally invasive procedures, is very exciting. Following on from our recent acquisition of Artoss in June this year, and Subiton and Synimed last year, Biocomposites has established itself as the go-to provider for surgeons requiring bone regeneration and/or managing infection in bone and soft tissue," Michael Harris, Biocomposites CEO.